ライフサイエンスコーパス: memorial

1 PCA-specific anxiety was measured with the Memorial Anxiety Scale for Prostate Cancer (MAX-PC).

2 istorical perspective the 1985 G.H.A. Clowes Memorial Award Lecture delivered by Dr. Judah Folkman.

3 Levin et al., conducted at the Roswell Park Memorial Cancer Institute in the 1940s.

4 In 2016, Tata Memorial Center in Mumbai, India, reached its platinum j

5 cted patients presenting to the S. P. Botkin Memorial Clinical Hospital of Infectious Diseases, St. P

6 ed Edmonton Symptom Assessment Scale (ESAS), Memorial Delirium Assessment Scale (MDAS), Nursing Delir

7 week using the Delirium Rating Scale and the Memorial Delirium Assessment Scale from 7 days before tr

8 week using the Delirium Rating Scale and the Memorial Delirium Assessment Scale.

9 elgene Corporation and Richard Spencer Lewis Memorial Foundation and Cancer Center Support Grant.

10 tutes of Health, Mayo Clinic, and Kathy Shih Memorial Foundation.

11 ation of Queensland, Kasey-Anne Oklobdzijato Memorial Fund, the Australasian Leukaemia and Lymphoma G

12 dy was performed on 218 CHD patients seen at Memorial Hermann Hospital during the influenza season of

13 Memorial Hermann Hospital, one of only two level I traum

14 tory MAC isolates from 131 patients at Grady Memorial Hospital (Atlanta) and 13 MAC isolates from the

15 secutively enrolled patients at Northwestern Memorial Hospital (Chicago, IL, USA) who were aged young

16 tients with <200 CD4 cells/mm3 seen at Grady Memorial Hospital (GMH), 11 (17%) of 66 with a history o

17 plication cohort from patients visiting Tata Memorial Hospital between Aug 4, 2015, and May 17, 2016,

18 patients admitted at the King Chulalongkorn Memorial Hospital during May 1, 2011 to Dec 31, 2013.

19 malignant GIST were admitted and treated at Memorial Hospital during the past 16 years.

20 analyzed patients at the Keelung Chung Gung Memorial Hospital during the period from March 2005 to J

21 er visiting all departments or units of Tata Memorial Hospital during the same time period and freque

22 ss-sectional study carried out in Minilik II Memorial Hospital eye clinic, Addis Ababa, Ethiopia from

23 metastases from sarcoma who were admitted to Memorial Hospital from 1982 to 2000, and 56 of them unde

24 derwent reduced intensity HSCT at Children's Memorial Hospital from January, 2000, to February, 2004.

25 s who enrolled at the Diabetes Unit of Grady Memorial Hospital in Atlanta, Georgia, from April 16, 19

26 ents entered by 1961 care providers at Grady Memorial Hospital in Atlanta, Georgia, to 15,534 Canonic

27 hly traumatized civilian population at Grady Memorial Hospital in Atlanta, Georgia.

28 in the emergency department (ED) at Parkland Memorial Hospital in Dallas, TX.

29 gram developed at Emory University and Grady Memorial Hospital is offered as a model for educating su

30 Wishard Memorial Hospital is the county hospital affiliated with

31 treated with platinum-based chemotherapy on Memorial Hospital protocols from 1975 to 1990 were analy

32 ugh March 31, 1987, using the Saint Margaret Memorial Hospital Rheumatoid Arthritis Registry, Pittsbu

33 gle-institution phase III trial conducted at Memorial Hospital served as the impetus for an intergrou

34 tential living donor at Kaohsiung Chang Gung Memorial Hospital were included.

35 elapsing-remitting MS, attended Northwestern Memorial Hospital, and despite treatment with interferon

36 s, we conducted a prospective study at Grady Memorial Hospital, Atlanta, Ga.

37 t oral/maxillofacial surgery clinic at Grady Memorial Hospital, Atlanta, GA.

38 rcus Stroke and Neuroscience Center at Grady Memorial Hospital, Atlanta, Georgia.

39 outpatient eye clinic of King Chulalongkorn Memorial Hospital, Bangkok, Thailand, and from the eye c

40 urban academic medical center (Northwestern Memorial Hospital, Chicago, Illinois).

41 BSC) between February to May to Northwestern Memorial Hospital, Chicago, was compared between the pre

42 lbladder cancer diagnosed or treated at Tata Memorial Hospital, Mumbai, India, and enrolled in the st

43 sed case-control study conducted at the Tata Memorial Hospital, Mumbai.

44 h strains were multi-resistant in Chang Gung Memorial Hospital, one of the biggest referral centers i

45 Movement Disorders Clinic in the Chang Gung Memorial Hospital, Taiwan.

46 Cone Memorial Hospital; this case became the landmark decisio

47 c effects." METHODS: CA-MHB and Roswell Park Memorial Institute (RPMI) 1640 medium (used for growing

48 ively) in an organ culture with Roswell Park Memorial Institute 1640 (30% serum) for 0, 4, 7, 10, and

49 e's medium/Ham's F12 (DMEM) and Roswell Park Memorial Institute 1640 medium (RPMI) supported the larg

50 nitive capacity for perceptual decisions and memorial judgments and used resting-state functional con

51 in metacognitive ability for perceptual and memorial judgments.

52 ts of my presentation at the Thomas W. Smith Memorial Lecture at American Heart Association Scientifi

53 s were studied in the Neonatal Unit, Simpson Memorial Maternity Pavilion, Edinburgh, UK.

54 ave birth at the University of Miami/Jackson Memorial Medical Center from 1990 through 2002.

55 s old, residing in Conemaugh Health System's Memorial Medical Center's service area.

56 retrospective study was conducted at Jackson Memorial-Miami Transplant Institute.

57 oring the beams of the National September 11 Memorial & Museum's "Tribute in Light" in New York, quan

58 dary outcomes were immediate change in mood (Memorial Pain Assessment Card) and 60-second heart and r

59 Primary outcomes were immediate (Memorial Pain Assessment Card, 0- to 10-point scale) and

60 can be taken to indicate that perceptual and memorial processes are not functionally independent, but

61 procedures to show that rats formed distinct memorial representations of 2 (peanut oil and sucrose pe

62 Prospective databases at Memorial Sloan Kettering (MSK), Massachusetts General Ho

63 e-body/-blood clearance (WB/BC) dosimetry at Memorial Sloan Kettering Cancer Center (MSKCC, n = 121).

64 e-body/-blood clearance (WB/BC) dosimetry at Memorial Sloan Kettering Cancer Center (MSKCC, n = 121).

65 sions from the dermatologic surgery units at Memorial Sloan Kettering Cancer Center and Oregon Health

66 s eligible for studies of targeted agents at Memorial Sloan Kettering Cancer Center are offered tumor

67 l of 4915 liver resections were performed at Memorial Sloan Kettering Cancer Center between 1992 and

68 ients referred to the Dermatology Service at Memorial Sloan Kettering Cancer Center between January 1

69 e indices in two independent cohorts of 154 (Memorial Sloan Kettering Cancer Center cohort [MSKCC] co

70 wn to attendees of a dermoscopy course (2014 Memorial Sloan Kettering Cancer Center dermoscopy course

71 ved intravitreous injections of melphalan at Memorial Sloan Kettering Cancer Center from September 12

72 fied National Institutes of Health criteria, Memorial Sloan Kettering Cancer Center GIST nomogram, an

73 Since 1962, Memorial Sloan Kettering Cancer Center has used an indiv

74 The overall accuracy of the Memorial Sloan Kettering Cancer Center nomogram was high

75 compared with the predictions of the updated Memorial Sloan Kettering Cancer Center nomogram.

76 ter screening 1,488 patients or relatives at Memorial Sloan Kettering Cancer Center or three related

77 Memorial Sloan Kettering Cancer Center risk category was

78 Randomisation was stratified by Memorial Sloan Kettering Cancer Center risk group and pa

79 Stratification factors were Memorial Sloan Kettering Cancer Center risk group and th

80 Geriatricians at Memorial Sloan Kettering Cancer Center risk-stratify sur

81 nt chemotherapy for advanced solid tumors at Memorial Sloan Kettering Cancer Center to report 12 comm

82 From January 2014 until May 2016 at Memorial Sloan Kettering Cancer Center, 10336 patients c

83 ts: For this cross-sectional cohort study at Memorial Sloan Kettering Cancer Center, 265 men with pro

84 , open-label clinical trial conducted at the Memorial Sloan Kettering Cancer Center, 60 patients 18 y

85 At Memorial Sloan Kettering Cancer Center, we have focused

86 HLA-A, HLA-B, and HLA-DRB1 was performed at Memorial Sloan Kettering Cancer Center.

87 31, 2017, at the Dermatology Service of the Memorial Sloan Kettering Cancer Center.

88 Cohorts were recruited from the Memorial Sloan Kettering Cancer Center; Melanoma Unit of

89 uenced between January 2014 and July 2015 at Memorial Sloan Kettering were recruited.

90 uenced between January 2014 and July 2015 at Memorial Sloan Kettering were recruited.

91 Lefkovsky Family Foundation; the Society of Memorial Sloan Kettering; the Byrne fund; and Cycle for

92 ent liver resection between 1995 and 2000 at Memorial Sloan- Kettering Cancer Center, we modeled the

93 id cancer and who were already enrolled in a Memorial Sloan-Kettering Cancer Center (131)I thyroid ca

94 hieved with that approach, as carried out at Memorial Sloan-Kettering Cancer Center (MSKCC) and as re

95 patients with no evidence of disease seen at Memorial Sloan-Kettering Cancer Center (MSKCC) between 1

96 All patients admitted to Memorial Sloan-Kettering Cancer Center (MSKCC) for curat

97 t diagnosis consecutively ascertained at the Memorial Sloan-Kettering Cancer Center (MSKCC) for incid

98 mSv for the reference population, the total Memorial Sloan-Kettering Cancer Center (MSKCC) study pat

99 inserted in adult and pediatric patients at Memorial Sloan-Kettering Cancer Center (MSKCC) were foll

100 eatment Referral Center protocol 9103 at the Memorial Sloan-Kettering Cancer Center (MSKCC) were revi

101 ) was developed from 127 patients treated at Memorial Sloan-Kettering Cancer Center (MSKCC), New York

102 itial endoscopic biopsies (EGDs) reviewed at Memorial Sloan-Kettering Cancer Center (MSKCC).

103 patients with newly diagnosed PCNSL seen at Memorial Sloan-Kettering Cancer Center (MSKCC; New York,

104 tients (n = 660) with breast cancer from the Memorial Sloan-Kettering Cancer Center (New York, NY) an

105 mogram was developed and is available on the Memorial Sloan-Kettering Cancer Center (New York, NY) We

106 static bladder cancer treated on protocol at Memorial Sloan-Kettering Cancer Center (New York, NY) wi

107 patients who were treated in this fashion at Memorial Sloan-Kettering Cancer Center (New York, NY).

108 ant prostate cancer in a validation set from Memorial Sloan-Kettering Cancer Center (New York, NY, US

109 resistant prostate cancer recruited from the Memorial Sloan-Kettering Cancer Center (New York, USA) w

110 Patients treated at the Memorial Sloan-Kettering Cancer Center between 1980 and

111 ndomized analysis of patients treated at the Memorial Sloan-Kettering Cancer Center between 1988 and

112 three-dimensional conformal radiotherapy at Memorial Sloan-Kettering Cancer Center between 1991 and

113 ients with metastatic uveal melanoma seen at Memorial Sloan-Kettering Cancer Center between 1994 and

114 radical prostatectomy for prostate cancer at Memorial Sloan-Kettering Cancer Center between December

115 s admitted to the special care unit (SCU) of Memorial Sloan-Kettering Cancer Center between January 1

116 nt stem-cell transplantation for lymphoma at Memorial Sloan-Kettering Cancer Center between January 2

117 ctive database for gastric adenocarcinoma at Memorial Sloan-Kettering Cancer Center between July 1985

118 senting with periampullary carcinomas to the Memorial Sloan-Kettering Cancer Center between October 1

119 ively reviewed all patients entered into the Memorial Sloan-Kettering Cancer Center clinical data bas

120 670 patients with advanced RCC treated in 24 Memorial Sloan-Kettering Cancer Center clinical trials b

121 By Memorial Sloan-Kettering Cancer Center criteria, 82% of

122 Examples from the Memorial Sloan-Kettering Cancer Center CST program are i

123 erformed of patients who had been treated at Memorial Sloan-Kettering Cancer Center for MCC between 1

124 tive SLN biopsy procedures were performed at Memorial Sloan-Kettering Cancer Center for unilateral in

125 ely maintained database for patients seen at Memorial Sloan-Kettering Cancer Center from 1996 to the

126 t of Surgery prospective gastric database at Memorial Sloan-Kettering Cancer Center from July 1985 to

127 tabase for adenocarcinoma of the pancreas at Memorial Sloan-Kettering Cancer Center identified 332 pa

128 ntify all patients who received cetuximab at Memorial Sloan-Kettering Cancer Center in a nonstudy set

129 athologic factors and the performance of the Memorial Sloan-Kettering Cancer Center nomogram for pred

130 ow risk for metastasis since the report from Memorial Sloan-Kettering Cancer Center of a 90% survival

131 ssigned, stratified by prior nephrectomy and Memorial Sloan-Kettering Cancer Center prognostic group,

132 dated computer system, and was stratified by Memorial Sloan-Kettering Cancer Center prognostic score

133 March 2002 to November 2006, 98 patients at Memorial Sloan-Kettering Cancer Center received inductio

134 Using the Memorial Sloan-Kettering Cancer Center sphincter functio

135 dy was to evaluate a published nomogram from Memorial Sloan-Kettering Cancer Center to predict for ri

136 advanced HCC treated over a 5-year period at Memorial Sloan-Kettering Cancer Center were identified f

137 sarcoma from July 1982 through July 1995 at Memorial Sloan-Kettering Cancer Center were the subject

138 d and entered into a prospective database at Memorial Sloan-Kettering Cancer Center with a diagnosis

139 ing nervous system'; Dr Richard Kolesnick's (Memorial Sloan-Kettering Cancer Center) talk has been fo

140 At Memorial Sloan-Kettering Cancer Center, a method for gen

141 2010, and January 1, 2013, was conducted at Memorial Sloan-Kettering Cancer Center, a tertiary refer

142 cations (Eastern Cooperative Oncology Group, Memorial Sloan-Kettering Cancer Center, and Heng criteri

143 At Memorial Sloan-Kettering Cancer Center, IHC incidence ha

144 lung and genitourinary cancer clinics in the Memorial Sloan-Kettering Cancer Center, New York, NY, US

145 known pulmonary process from 1996 to 1998 at Memorial Sloan-Kettering Cancer Center, were retrospecti

146 eatic adenocarcinoma nomogram established at Memorial Sloan-Kettering Cancer Center.

147 low-up endoscopic gastroduodenal biopsies at Memorial Sloan-Kettering Cancer Center.

148 ly analyzed by G-banding, ascertained at the Memorial Sloan-Kettering Cancer Center.

149 tion from December 1991 to September 2001 at Memorial Sloan-Kettering Cancer Center.

150 Anderson Cancer Center in collaboration with Memorial Sloan-Kettering Cancer Center.

151 93 to December 1997 with ICE chemotherapy at Memorial Sloan-Kettering Cancer Center.

152 tissue sarcoma were admitted and treated at Memorial Sloan-Kettering Cancer Center.

153 Cancer Institute and CycleforSurvival Fund, Memorial Sloan-Kettering Cancer Center.

154 alt Lake City, UT), in pediatric patients at Memorial Sloan-Kettering Cancer Center.

155 spective case control study was conducted at Memorial Sloan-Kettering Cancer Center.

156 ateral breast cancer underwent mastectomy at Memorial Sloan-Kettering Cancer Center.

157 metastatic samples from a clinical cohort at Memorial Sloan-Kettering Cancer Center.

158 prospectively on 3 consecutive protocols at Memorial Sloan-Kettering Cancer Center.

159 York City, New York, the predecessor of the Memorial Sloan-Kettering Center for the Treatment of Can

160 venty-three patients with OS were treated at Memorial-Sloan Kettering Cancer Center (MSKCC) on the T1

161 tric adenocarcinoma underwent laparoscopy at Memorial-Sloan Kettering Cancer Center from December 199

162 Review of prospectively collected data at Memorial-Sloan Kettering Cancer Center was conducted.

163 pirit during its traverses from the Columbia Memorial station to Bonneville crater were determined wi

164 windblown sediments are seen at the Columbia Memorial Station where the Spirit rover landed.

165 st are present in the soil near the Columbia Memorial Station.

166 age- and respondent-adapted versions of the Memorial Symptom Assessment Scale (MSAS), Pediatric Qual

167 Outcomes Study (MOS) questionnaire, and the Memorial Symptom Assessment Scale (MSAS)--as well as ori

168 h patient at baseline and serially using the Memorial Symptom Assessment Scale (MSAS)-Global Distress

169 respondent-adapted versions of the PediQUEST Memorial Symptom Assessment Scale (PQ-MSAS) at most once

170 I, -0.37 to 0.53 points]), symptom distress (Memorial Symptom Assessment Scale global distress index,

171 utcomes of interest were all other symptoms (Memorial Symptom Assessment Scale) and quality of life (

172 re, 0- to 10-point scale), symptom distress (Memorial Symptom Assessment Scale, 0- to 4-point scale),

173 a modification of the Condensed Form of the Memorial Symptom Assessment Scale.